{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:15:04Z","timestamp":1793243704645,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Doxil\u00ae, a PEGylated liposomal doxorubicin (DOX) hydrochloride suspension, was the first liposome drug product approved by the U.S. Food and Drug Administration (FDA). Although off-patent, limited generic products have been approved due to challenges in achieving bioequivalence compounded by manufacturing complexity. Regulatory agencies require generic drug products to be bioequivalent to the reference listed drug. In this regard, we developed various analytical methods to analyze Doxil\u00ae and its generic drug products for multiple attributes, including liposome size distribution, zeta potential, DOX content, lipid content, purity, non-encapsulated doxorubicin, morphology, nanostructure similarity, and quantified\n                    <jats:italic>in vitro<\/jats:italic>\n                    release. Batch-to-batch variation exists across attributes for different formulations. Minor differences in particle size and zeta potential were observed. Cryo-TEM imaging reveals the distinct coffee bean shape and morphology of the Doxil\u00ae liposome. SAXS similarity analysis shows a distinct difference in\u00a0nanostructure for Dr. Reddy\u2019s formulation compared to the innovator formulation. Still, it is revealed to be a consequence of liposome uniformity and homogeneity as depicted in cryo-TEM images. Several methods developed in this work can be complementary to provide a more thorough physicochemical analysis for generic evaluation. Size, morphology, and nanostructure evaluated by DLS, cryo-TEM, and SAXS should be readily employed to assess physicochemical similarity. Content, impurity identification, and amount of free non-encapsulated DOX are used to evaluate formulation sameness. The methods developed in this work provide a physicochemical framework for analytical comparison of complex liposomal generics and may support subsequent development efforts to improve generic drug availability for patient populations in need.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-025-01058-1","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T17:52:57Z","timestamp":1748886777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Comparative Study on Physicochemical and Analytical Characterizations of Doxil\u00ae and its Generic Drug Products"],"prefix":"10.1208","volume":"27","author":[{"given":"Adaeze","family":"Eneli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaikai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimpy","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-8080","authenticated-orcid":false,"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"1058_CR1","unstructured":"Global doxorubicin market trajectory & analytics report 2022\u20132026: Rising Incidence of cancers & development of technologically advanced systems for drug delivery driving growth [Internet]. GlobeNewswire News Room. 2022 [cited 2024 Jun 25]. Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2022\/05\/25\/2450132\/28124\/en\/Global-Doxorubicin-Market-Trajectory-Analytics-Report-2022-2026-Rising-Incidence-of-Cancers-Development-of-Technologically-Advanced-Systems-for-Drug-Delivery-Driving-Growth.html. Accessed 24 Jun 2024."},{"key":"1058_CR2","unstructured":"Ghosh S. Liposomal doxorubicin market outlook for 2024\u20132034 [Internet]. 2024 [cited 2024 Jun 25]. Available from: https:\/\/www.futuremarketinsights.com\/reports\/liposomal-doxorubicin-market. Accessed\u00a025 Jun 2024."},{"key":"1058_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/molecules28010010","volume":"28","author":"W Alshaer","year":"2022","unstructured":"Alshaer W, Nsairat H, Lafi Z, Hourani OM, Al-Kadash A, Esawi E, et al. Quality by design approach in liposomal formulations: robust product development. Molecules. 2022;28:10.","journal-title":"Molecules"},{"key":"1058_CR4","unstructured":"FDA CDER, Mahadevan C. Draft guidance on doxorubicin hydrochloride. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_050718.pdf. Accessed\u00a025 Jun 2024."},{"key":"1058_CR5","unstructured":"Food and Drug Administration. 21 CFR 320.22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence [Internet]. 2002. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-320\/subpart-B\/section-320.22. Accessed\u00a018 Jul 2024."},{"key":"1058_CR6","unstructured":"Food and Drug Administration D of H and HS. 21 CFR 320.24 Types of evidence to measure bioavailability or establish bioequivalence [Internet]. 2002. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/part-320\/section-320.24. Accessed\u00a025 Jun 2024."},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"122952","DOI":"10.1016\/j.ijpharm.2023.122952","volume":"639","author":"M Yu","year":"2023","unstructured":"Yu M, Yuan W, Xia Z, Liu Y, Wang Y, Xu X, et al. Characterization of exparel bupivacaine multivesicular liposomes. Int J Pharm. 2023;639:122952.","journal-title":"Int J Pharm"},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejpb.2020.09.008","volume":"157","author":"Y Liu","year":"2020","unstructured":"Liu Y, Mei Z, Mei L, Tang J, Yuan W, Srinivasan S, et al. Analytical method development and comparability study for Am Bisome\u00ae and generic Amphotericin B liposomal products. Eur J Pharm Biopharm. 2020;157:241\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"1058_CR9","unstructured":"Food and Drug Administration. Orange book: Approved drug products with therapeutic equivalence evaluations [Internet]. [cited 2024 Jun 25]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm. Accessed 25 Jun 2024."},{"key":"1058_CR10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1017\/S1431927603445911","volume":"9","author":"DN Mastronarde","year":"2003","unstructured":"Mastronarde DN. SerialEM: A program for automated tilt series acquisition on Tecnai microscopes using prediction of specimen position. Microsc Microanal. 2003;9:1182\u20133.","journal-title":"Microsc Microanal"},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","volume":"152","author":"DN Mastronarde","year":"2005","unstructured":"Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. J Struct Biol. 2005;152:36\u201351.","journal-title":"J Struct Biol"},{"key":"1058_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"1058_CR13","unstructured":"SIBYLS MailinSAXS HT-SAXS Instructions [Internet]. 2010 [cited 2024 Jun 4]. Available from: https:\/\/htsaxs.bl1231.als.lbl.gov\/htsaxs. Accessed\u00a027 Jun 2024."},{"key":"1058_CR14","unstructured":"U.S. Food & Drug Administration. Compilation of FDA guidance and resources for in vitro dissolution testing of immediate release solid oral dosage forms. FDA [Internet]. 2024 [cited 2025 Feb 13]. Available from: https:\/\/www.fda.gov\/animal-veterinary\/new-animal-drug-applications\/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage. Accessed 13 Feb 2025."},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1208\/s12248-016-9958-2","volume":"19","author":"W Yuan","year":"2017","unstructured":"Yuan W, Kuai R, Dai Z, Yuan Y, Zheng N, Jiang W, et al. Development of a flow-through USP-4 apparatus drug release assay to evaluate doxorubicin liposomes. AAPS J. 2017;19:150\u201360.","journal-title":"AAPS J"},{"key":"1058_CR16","unstructured":"Food and Drug Administration. Doxil label [Internet]. Food and Drug Administration. 1995. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf. Accessed 19 Jun 2024."},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1017\/S1431927617006742","volume":"23","author":"Y Wu","year":"2017","unstructured":"Wu Y, Petrochenko P, Szoka FC, Manna S, Koo B, Zheng N, et al. Cryogenic Transmission Electron Microscopy (Cryo-TEM) reveals morphological changes of liposomal doxorubicin during In Vitro release. Microsc Microanal. 2017;23:1216\u20137.","journal-title":"Microsc Microanal"},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/bs.mie.2022.09.024","volume":"678","author":"DT Murray","year":"2023","unstructured":"Murray DT, Shin DS, Classen S, Brosey CA, Hura GL. Visualizing and accessing correlated SAXS data sets with similarity maps and simple scattering web resources. Methods Enzymol. 2023;678:411\u201340.","journal-title":"Methods Enzymol"},{"key":"1058_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4155\/bio.10.204","volume":"3","author":"W Jiang","year":"2011","unstructured":"Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis. 2011;3:333\u201344.","journal-title":"Bioanalysis"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2174\/1871520617666171121124610","volume":"18","author":"K Maiti","year":"2018","unstructured":"Maiti K, Bhowmick S, Jain P, Zope M, Doshi K, Rajamannar T. Comparison of physicochemical properties of generic doxorubicin HCl liposome injection with the reference listed drug. Anticancer Agents Med Chem. 2018;18:597\u2013609.","journal-title":"Anticancer Agents Med Chem"},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"113491","DOI":"10.1016\/j.colsurfb.2023.113491","volume":"230","author":"IDL Souza","year":"2023","unstructured":"Souza IDL, Saez V, Mansur CRE. Lipid nanoparticles containing coenzyme Q10 for topical applications: an overview of their characterization. Colloids Surf B Biointerfaces. 2023;230:113491.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1058_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2016.06.017","volume":"235","author":"S Bhattacharjee","year":"2016","unstructured":"Bhattacharjee S. DLS and zeta potential \u2013 What they are and what they are not? J Controlled Release. 2016;235:337\u201351.","journal-title":"J Controlled Release"},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1007\/s00216-017-0527-z","volume":"409","author":"MC Smith","year":"2017","unstructured":"Smith MC, Crist RM, Clogston JD, McNeil SE. Zeta potential: a case study of cationic, anionic, and neutral liposomes. Anal Bioanal Chem. 2017;409:5779\u201387.","journal-title":"Anal Bioanal Chem"},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijcard.2006.05.005","volume":"117","author":"D Outomuro","year":"2007","unstructured":"Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol. 2007;117:6\u201315.","journal-title":"Int J Cardiol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01058-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:51:44Z","timestamp":1751622704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01058-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01058-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Schwendeman declares financial interests for board membership, as a paid consultant, for research funding, and\/or as equity holder in EVOQ Therapeutics and ASKO Pharma. The University of Michigan has a financial interest in EVOQ Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}}],"article-number":"100"}}